ContraFect Overview
Valuation check: CFRX's ROE is 382.48%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow382.48%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
ContraFect (CFRX) currently reports a ROE of 382.48%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore ContraFect's ROE history and peer comparisons.
ContraFect's ROE of 382.48% is higher than the Healthcare sector average of 21.67%. That is roughly 1665.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but ContraFect's current 382.48% should be judged against Healthcare norms (sector average: 21.67%) and against CFRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 382.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for ContraFect, and consider following CFRX for alerts when major investors trade the stock.
ContraFect is classified in the Healthcare sector. On ROE, it currently shows 382.48% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CFRX with unrelated industries.
